Small nucleolar RNA 42 promotes the growth of hepatocellular carcinoma through the p53 signaling pathway.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
10 Nov 2021
10 Nov 2021
Historique:
received:
12
07
2021
accepted:
20
10
2021
revised:
15
10
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Recent studies show that small nucleolar RNAs (snoRNAs) play an important role in tumorigenesis. SNORA42 is a potential therapeutic target and prognostic biomarker for various cancers, and the aim of the present study was to investigate the function and clinical relevance of SNORA42 in hepatocellular carcinoma (HCC). We detected the expression levels of SNORA42 in HCC and normal liver tissue samples, as well as in tumor and hepatocyte-derived cell lines. SNORA42 was significantly upregulated in the HCC tissues and cells compared to the adjacent liver tissues and normal hepatocytes. Furthermore, overexpression of SNORA42 correlated with poor prognosis in the HCC patients. Knocking down SNORA42 in HCC cell lines decreased their proliferation, migration and invasion in vitro, and inhibited tumor growth and metastasis in vivo. In contrast, ectopic expression of SNORA42 promoted HCC cell proliferation and inhibited apoptosis. Mechanistically, SNORA42 exerted its oncogenic effects by targeting the p53 signaling pathway and cell cycle transition. In conclusion, SNORA42 acted as an oncogene in HCC and was a potential prognostic biomarker and therapeutic target.
Identifiants
pubmed: 34759267
doi: 10.1038/s41420-021-00740-5
pii: 10.1038/s41420-021-00740-5
pmc: PMC8581050
doi:
Types de publication
Journal Article
Langues
eng
Pagination
347Informations de copyright
© 2021. The Author(s).
Références
Cancers (Basel). 2019 Aug 14;11(8):
pubmed: 31416295
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188556
pubmed: 33932560
Biosci Trends. 2021 Jul 6;15(3):138-141
pubmed: 33746184
BMC Genomics. 2016 Nov 24;17(1):969
pubmed: 27881081
Oncogene. 2013 Oct 24;32(43):5129-43
pubmed: 23416979
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Cell Death Differ. 2018 Jan;25(1):133-143
pubmed: 29125602
Oncotarget. 2016 Sep 13;7(37):59519-59534
pubmed: 27517747
Oncogene. 2012 May 31;31(22):2794-804
pubmed: 21986946
Nat Rev Immunol. 2016 Dec;16(12):741-750
pubmed: 27667712
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Oncologist. 2019 Oct;24(10):e990-e1005
pubmed: 31217342
Chin Med J (Engl). 2021 Mar 17;134(7):783-791
pubmed: 33734139
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96
pubmed: 33408363
Int J Biochem Cell Biol. 2018 Sep;102:138-150
pubmed: 30053504
Ann Surg Oncol. 2018 Apr;25(4):991-999
pubmed: 29327179
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Cell Death Dis. 2021 Jul 9;12(7):691
pubmed: 34244479
Lancet. 2019 Sep 28;394(10204):1145-1158
pubmed: 31248666
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Gut. 2017 Jan;66(1):107-117
pubmed: 26475630
Value Health Reg Issues. 2018 May;15:120-126
pubmed: 29704658
Mol Cancer. 2010 Jul 27;9:198
pubmed: 20663213